Myconostica Awarded Prestigious ‘Innovation in Diagnostics Project of the Year’ by Bionow

Myconostica Ltd, a UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces that it has been awarded the esteemed ‘Innovation in Diagnostics Project of the Year’ title at this year’s Northwest Biomedical Awards Dinner. The award was received for Myconostica’s MycArrayTM Yeast ID product; an inventive system for identifying Candida species.  

MycArrayTM Yeast ID utilises microarray technology to identify 18 different yeast species from yeast positive blood cultures. Several Candida species are well-documented as exhibiting resistance or a decreased susceptibility to certain anti-fungal drugs commonly used in the treatment of invasive yeast infections. Rapid and accurate identification of Candida species in patients suffering from candidemia is imperative for clinicians thus enabling correct anti-fungal therapies to be administered. Studies have shown that the administration of targeted therapies in patients with candidemia significantly improve patient outcomes. In excess of 100,000 people globally are believed to suffer from invasive infections caused by Candida species each year.  

Dr. John Thornback, Myconostica’s Chief Operating Officer, received the honour on behalf of the company at the award ceremony. Speaking at the event, Dr. Thornback said “Myconostica are delighted to have received this title in recognition of the innovative technology utilised in our original test for identifying Candida species, MycArrayTM Yeast ID. Having been the recipients of Bionow’s Biomedical Start Up of the Year Award in 2006 we are delighted to have been further recognised for our continued contribution to providing innovative diagnostic solutions for the treatment of invasive fungal diseases”.  

The Northwest Biomedical Awards are held annually by Bionow to formally recognise the excellence and efforts of Northwest companies within the biomedical sector. Bionow is the cluster support group for the Northwest of England's biotechnology, pharmaceutical and healthcare industry. 

For further information please contact: 

Myconostica Ltd

Dr. Francesca Sadler, Sales & Marketing Manager:

+44 (0)161 998 7239 

Media Enquiries:

Cardew Group

Tim Robertson/ Matthew Law 
+44 020 7930 0777 

About Myconostica Ltd.

Myconostica Ltd, a UK-based medical diagnostic company specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow.  Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy.

Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.

On the web: